DAS-181

Overview

DAS-181 is under investigation in clinical trial NCT00527865 (Single Dose Escalating Study of DAS181 in Adults).

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
Worldwide Trends on COVID-19 Research After the Declaration of COVID-19 Pandemic	2020/07/07	NCT04460547	N/A	UNKNOWN	Qassim University
DAS181 for STOP COVID-19	2020/04/21	NCT04354389	Phase 2	Withdrawn	Ansun Biopharma, Inc.
DAS181 for Severe COVID-19: Compassionate Use	2020/03/27	NCT04324489	Not Applicable	Completed	Renmin Hospital of Wuhan University
DAS181 for Patients With Severe Hospitalized Flu and SAD-RVs (COVID-19)	2020/03/06	NCT04298060	Phase 2	UNKNOWN	Ansun Biopharma, Inc.
Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study	2019/01/18	NCT03808922	Phase 3	Recruiting	Ansun Biopharma, Inc.
Influenza Antiviral DAS-181-F04 in Healthy Adults	2012/07/27	NCT01651494	Phase 1	Completed	National Institute of Allergy and Infectious Diseases (NIAID)
DAS181 in Patients With Parainfluenza	2011/09/27	NCT01441024	Phase 2	Withdrawn	National Institute of Allergy and Infectious Diseases (NIAID)
Influenza Antiviral DAS181-F03	2010/07/30	NCT01173224	Phase 1	Completed	National Institute of Allergy and Infectious Diseases (NIAID)
DAS181 Single Dose Escalation Study in Healthy Adults	2009/04/06	NCT00876161	Phase 1	Completed	Ansun Biopharma, Inc.
Single Dose Escalating Study of DAS181 in Adults	2007/09/11	NCT00527865	Phase 1	Completed	Ansun Biopharma, Inc.

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

Related News

Novavax Launches Clinical Trial for JN.1 Subvariant COVID-19 Vaccine

7 months ago

Novavax initiates a new clinical trial to evaluate the safety and immunogenicity of its JN.1 subvariant vaccine (NVX CoV2705) with Matrix-M adjuvant. The study will compare results with the previously authorized NVX-CoV2601 vaccine, marking a significant step in addressing emerging COVID-19 variants.

Help Us Improve

Your feedback helps us provide better drug information and insights.

AI-Powered Research

Premium Access